Overview Latest Regional Industry Featured Multimedia Other Languages Public Company News
All APAC Global
All APAC Global
All APAC Global
All APAC Global
CARsgen Announced 2023 Interim Results 2023-08-22 19:30
Kintor Pharma Announces Completion of Patient Enrollment in Phase II Clinical Trial of GT20029 for Treatment of Androgenetic Alopecia in China 2023-08-22 17:13
Introducing NeoMab™: GemPharmatech's Innovative Antibody Gene Humanized Mouse Model 2023-08-22 08:59
CanariaBio Achieves Significant Milestone with FDA's Orphan Drug Designation for MAb-AR20.5 Targeting Pancreatic Cancer 2023-08-21 20:00
TradeUP Acquisition Corp. Announces Extension of the Deadline for an Initial Business Combination 2023-08-19 04:30
Akeso Announced First Patient Dosed in Phase 3 Trial of Ivonescimab versus Tislelizumab for First-line Treatment of Squamous NSCLC 2023-08-18 20:00
Inmagene's anti-OX40 mAb demonstrated an extended half-life and a favorable safety profile in a Phase I study 2023-08-18 19:00
JinMed (NASDAQ: ZJYL) Rings the Nasdaq Stock Market Closing Bell on August 17 2023-08-18 11:36
Thrombotic AEs of Hemlibra (emicizumab) were 2.8 times more frequent than those of FVIII replacements. 2023-08-18 08:58
Neurophth Announces First Patient Dosed in Phase I/II Clinical Trial of Second Gene Therapy 2023-08-17 21:00
Minghui Pharmaceutical Inc. Announces First Patient Enrollment in the Phase 3 Clinical Study of MH004 Cream for Treatment of Mild to Moderate Atopic Dermatitis 2023-08-17 19:00
I-Mab Provides Mid-Year 2023 Financial Results, Business and Corporate Updates 2023-08-17 18:00
2023WCLC Oral Presentation | Molecular Analysis Validates the Effectiveness of Tumor Tissue-Based and Plasma ctDNA Testing in Identifying NSCLC Patients with EGFR Exon20ins Eligible for Treatment with Sunvozertinib 2023-08-17 17:10
Nippon Express (Ireland) Opens New Warehouse in Dublin, Beginning Operations July 1 2023-08-16 14:00
Inmagene's OX40 mAb, with an extended half-life and silenced ADCC, enters POC study in Atopic Dermatitis 2023-08-15 22:50
OnCusp Therapeutics Receives FDA Clearance for the Phase 1 Clinical Trial of CUSP06, Targeting Ovarian Cancer and Other Advanced Solid Tumors 2023-08-15 20:00
Asieris Announces Positive Phase III Bridging Trial of Hexvix®, a Diagnostic Drug for Bladder Cancer 2023-08-11 17:00
WuXi XDC and Boostimmune Sign MOU for Integrated Services 2023-08-11 08:30
Standigm and Nashville Biosciences join to revolutionize early drug discovery 2023-08-10 21:07
Oricell OriCAR-017 CAR-T Therapy Clears IND Hurdle, Paving the Way for Global Impact 2023-08-10 21:00
1 23 24 25 26 27 148